The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the treatment of bladder cancer. The PD-1/antibody-drug conjugate pairing ...

Adenocarcinoma of the bladder is rare, originating from glandular cells, and can be primary or secondary, requiring accurate diagnosis for appropriate treatment. Diagnosis involves cystoscopy, biopsy, ...

Scientists uncovered how childhood BK virus infections may set off cancer-causing mutations decades later: by activating a host immune system enzyme that attacks DNA. When you purchase through links ...

Scientists have found that analyzing cfDNA fragments in urine may allow bladder cancer to be diagnosed and monitored without invasive procedures, revealing biomarkers that could transform patient care ...

Bladder cancer is a highly heterogeneous malignant tumor of the urinary system with high recurrence rates, posing significant challenges in its diagnosis and treatment. Advances in multi-omics ...

Learning the symptoms of bladder cancer may help you identify this cancer in its earliest stages before it grows or spreads beyond your bladder. While other conditions may also cause similar symptoms, ...

Squamous cell carcinoma of the bladder is rare, accounting for 2% to 5% of bladder cancers in the U.S., and is linked to chronic bladder irritation. Diagnosis involves cystoscopy, biopsy, and imaging ...

The FDA has approved Pfizer and Astellas’ Padcev (enfortumab vedotin-ejfv) plus Merck’s Keytruda (pembrolizumab) as a perioperative treatment for adults with muscle-invasive bladder cancer who are ...

“Bladder cancer, especially in its high-grade form, is a serious and often aggressive disease. Detecting it early is key,” says fourth-year Brady resident Michelle Higgins, M.D. “Unfortunately, there ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...

Editor's Note: This is an excerpt from WBUR's weekly health newsletter, CommonHealth. If you like what you read and want it in your inbox, sign up here. Bladder cancer hits men especially hard. The ...

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, consistent release of chemotherapy proved far more effective than traditional ...